Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Buy" from Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $13.39.

Several research firms recently issued reports on VYGR. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, April 8th.

Voyager Therapeutics Trading Down 8.3%

Shares of VYGR traded down $0.30 during midday trading on Tuesday, reaching $3.30. 913,503 shares of the company were exchanged, compared to its average volume of 476,197. Voyager Therapeutics has a 1-year low of $2.65 and a 1-year high of $9.55. The company has a market cap of $182.61 million, a price-to-earnings ratio of 4.65 and a beta of 0.82. The stock has a 50-day moving average price of $3.25 and a 200-day moving average price of $4.40.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. Equities research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics in the fourth quarter valued at $29,000. Tower Research Capital LLC TRC lifted its position in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares during the period. CWM LLC grew its position in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the last quarter. Finally, Oxford Asset Management LLP bought a new stake in shares of Voyager Therapeutics during the fourth quarter valued at approximately $60,000. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.